Purpose: This study aimed to investigate the efficacy and safety of combining cinobufotalin and chemotherapy for advanced gastric cancer (GC).
Patients and methods: Literature retrieval was performed in Cochrane Library, Web of Science, PubMed, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biological Medicine Database (CBM), Wanfang database and Chinese Scientific Journal Database (VIP) before September 2018. The primary reported outcomes including therapeutic efficacy, quality of life (QoL), and adverse events were systematically evaluated.
Results: Data from 27 trials including 1,939 advanced GC patients were included. The results indicated that, compared with chemotherapy alone, the combination of chemotherapy and cinobufotalin significantly improved patients’ overall response rate (odds ratio [OR] =1.88, 95% confidence interval [CI] =1.54–2.31, P <0.00001) and disease control rate (OR =2.05, 95% CI =1.63–2.58, P <0.00001). The QoL of patients also evidently improved after chemotherapy and cinobufotalin combined treatment, as indicated by increased QoL improved rate (OR =2.39, 95% CI =1.81–3.15, P <0.00001), Karnofsky Performance Score (OR =7.00, 95% CI =2.25–11.75, P =0.004) and pain relief rate (OR =7.00, 95% CI =2.25–11.75, P =0.004). Adverse events including nausea and vomiting, diarrhea, leukopenia, hand-foot syndrome, anemia, gastrointestinal side effects and peripheral neurotoxicity caused by chemotherapy were evidently alleviated (P <0.05) when cinobufotalin was administered to GC patients.
Conclusion: Evidence from the meta-analysis suggested that the combination of chemotherapy and cinobufotalin is more effective in treating GC than chemotherapy alone. It alleviates the adverse effects associated with chemotherapy and improves the QoL of GC patients.
Keywords: cinobufotalin, traditional Chinese medicine, chemotherapy, gastric cancer, meta-analysis